<DOC>
	<DOCNO>NCT01153906</DOCNO>
	<brief_summary>The purpose post-marketing study evaluate incidence autoimmune disease ( AIDs ) follow female receive least first dose Cervarix® part routine health care .</brief_summary>
	<brief_title>Post-marketing Safety Study Autoimmune Diseases Following Cervarix® Vaccination</brief_title>
	<detailed_description />
	<mesh_term>Autoimmune Diseases</mesh_term>
	<criteria>Both cohort : Have complete medical insurance coverage pharmacy benefit . Enrolled female health plan member least one year prior study entry . Age 9 25 year study entry . Exposed cohort : • Subjects receive least one dose Cervarix® , without US ageappropriate recommend vaccine . Unexposed cohort : • No specific inclusion criterion Both cohort : • Subjects diagnostic code AID endpoints interest one year prior index date . Exposed cohort : • Subjects receive dose Gardasil® prior first dose Cervarix® . Unexposed cohort : • Subjects receive dose Cervarix® prior index date .</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>autoimmune disease</keyword>
	<keyword>HPV vaccine</keyword>
	<keyword>papillomavirus</keyword>
	<keyword>human papillomavirus</keyword>
	<keyword>HPV</keyword>
</DOC>